The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1988-07

AUTHORS

V. Rovei, J. Escourrou, G. Campistron, D. Ego, A. Thiola, A. Ribet, G. Houin

ABSTRACT

We have studied the pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, in 11 patients with hepatic cirrhosis after the oral administration of a single 500 mg tablet of bendazac-lysine, and compared them with those obtained from 10 healthy adults. The rate of absorption of bendazac, as assessed by tmax and Cmax, is similar in patients and in healthy subjects. The drug is eliminated mostly by metabolism in healthy adults, more than 60% of the dose being excreted in the urine as 5-hydroxybendazac and its glucuronide. Hepatic insufficiency impairs this metabolism, a two-fold decrease in apparent plasma clearance (CL/f) being observed in the patients. Although the plasma unbound fraction of bendazac is increased in patients (the drug is highly bound to plasma albumin), the apparent volume of distribution (V/f) is unchanged. In consequence, the half-life of bendazac is increased two-fold in the patients. Impairment of metabolism decreases the formation of 5-hydroxybendazac, but metabolism remains the main route of its elimination. Renal excretion of bendazac accounts for about 10% of the dose in both patients with cirrhosis and healthy subjects. We conclude that in patients with severe hepatic insufficiency the daily dose of bendazac-lysine should be halved. More... »

PAGES

391-396

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00561370

DOI

http://dx.doi.org/10.1007/bf00561370

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036705253

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3197747


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Binding", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Centre de Recherche Delalande, Rueil Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rovei", 
        "givenName": "V.", 
        "id": "sg:person.01177602577.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177602577.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Rangueil", 
          "id": "https://www.grid.ac/institutes/grid.414295.f", 
          "name": [
            "Service des Maladies de l'Appareil Digestif, C.H.U. Rangueil, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escourrou", 
        "givenName": "J.", 
        "id": "sg:person.01326516170.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326516170.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Purpan", 
          "id": "https://www.grid.ac/institutes/grid.414282.9", 
          "name": [
            "Unit\u00e9 de Pharmacocin\u00e9tique Clinique, C.H.U. Purpan, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Campistron", 
        "givenName": "G.", 
        "id": "sg:person.0720752245.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720752245.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centre de Recherche Delalande, Rueil Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ego", 
        "givenName": "D.", 
        "id": "sg:person.01205714133.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205714133.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centre de Recherche Delalande, Rueil Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thiola", 
        "givenName": "A.", 
        "id": "sg:person.01135446267.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135446267.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Rangueil", 
          "id": "https://www.grid.ac/institutes/grid.414295.f", 
          "name": [
            "Service des Maladies de l'Appareil Digestif, C.H.U. Rangueil, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ribet", 
        "givenName": "A.", 
        "id": "sg:person.0763747335.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763747335.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Purpan", 
          "id": "https://www.grid.ac/institutes/grid.414282.9", 
          "name": [
            "Unit\u00e9 de Pharmacocin\u00e9tique Clinique, C.H.U. Purpan, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Houin", 
        "givenName": "G.", 
        "id": "sg:person.01347523716.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347523716.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0031-6989(83)80066-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007332006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0163-7258(81)90077-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010634790"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0163-7258(81)90077-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010634790"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-4809(78)90017-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012957660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-4809(78)90017-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012957660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00637567", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019827959", 
          "https://doi.org/10.1007/bf00637567"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00637567", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019827959", 
          "https://doi.org/10.1007/bf00637567"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600680948", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023750024"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600660402", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036399043"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-197702010-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048454128", 
          "https://doi.org/10.2165/00003088-197702010-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-197702010-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048454128", 
          "https://doi.org/10.2165/00003088-197702010-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(81)90151-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048734253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(81)90151-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048734253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081861849", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082164662", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1988-07", 
    "datePublishedReg": "1988-07-01", 
    "description": "We have studied the pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, in 11 patients with hepatic cirrhosis after the oral administration of a single 500 mg tablet of bendazac-lysine, and compared them with those obtained from 10 healthy adults. The rate of absorption of bendazac, as assessed by tmax and Cmax, is similar in patients and in healthy subjects. The drug is eliminated mostly by metabolism in healthy adults, more than 60% of the dose being excreted in the urine as 5-hydroxybendazac and its glucuronide. Hepatic insufficiency impairs this metabolism, a two-fold decrease in apparent plasma clearance (CL/f) being observed in the patients. Although the plasma unbound fraction of bendazac is increased in patients (the drug is highly bound to plasma albumin), the apparent volume of distribution (V/f) is unchanged. In consequence, the half-life of bendazac is increased two-fold in the patients. Impairment of metabolism decreases the formation of 5-hydroxybendazac, but metabolism remains the main route of its elimination. Renal excretion of bendazac accounts for about 10% of the dose in both patients with cirrhosis and healthy subjects. We conclude that in patients with severe hepatic insufficiency the daily dose of bendazac-lysine should be halved.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00561370", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis", 
    "pagination": "391-396", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "aed9c08ebcccf18e097d74a420ab76fe12092edbcba83769b9a191e88f3b5af9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3197747"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00561370"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036705253"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00561370", 
      "https://app.dimensions.ai/details/publication/pub.1036705253"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130808_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00561370"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00561370'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00561370'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00561370'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00561370'


 

This table displays all metadata directly associated to this object as RDF triples.

194 TRIPLES      21 PREDICATES      50 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00561370 schema:about N0f52908a78ac425da0ca95213d63862a
2 N4f6fd1b97bca418aabf7d47a8913e1b0
3 N559425129ab44137a692a8a8847bfa60
4 N9cf03ad30c1f4df0a7e401342ba5ac98
5 Na4c7e67fdfa64ee2b9bbe4b6bf743f74
6 Naefd3b052e654fcd88caa2bcc93c71d1
7 Nc6540cf887984a008f00d8dd18ffa74f
8 Nd16168e8d3484f289c6818015e0f9532
9 Ne4ff77b408364620a95de595410b91ce
10 Ne7ef6fe7e4d0441a9fc057274a1f636b
11 Nf96a6baba2564660a7551b596293adbe
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author Nfd3ce03afb2c4778afacda7104b94e9c
15 schema:citation sg:pub.10.1007/bf00637567
16 sg:pub.10.2165/00003088-197702010-00003
17 https://app.dimensions.ai/details/publication/pub.1081861849
18 https://app.dimensions.ai/details/publication/pub.1082164662
19 https://doi.org/10.1002/jps.2600660402
20 https://doi.org/10.1002/jps.2600680948
21 https://doi.org/10.1016/0006-2952(81)90151-9
22 https://doi.org/10.1016/0010-4809(78)90017-4
23 https://doi.org/10.1016/0163-7258(81)90077-2
24 https://doi.org/10.1016/s0031-6989(83)80066-6
25 schema:datePublished 1988-07
26 schema:datePublishedReg 1988-07-01
27 schema:description We have studied the pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, in 11 patients with hepatic cirrhosis after the oral administration of a single 500 mg tablet of bendazac-lysine, and compared them with those obtained from 10 healthy adults. The rate of absorption of bendazac, as assessed by tmax and Cmax, is similar in patients and in healthy subjects. The drug is eliminated mostly by metabolism in healthy adults, more than 60% of the dose being excreted in the urine as 5-hydroxybendazac and its glucuronide. Hepatic insufficiency impairs this metabolism, a two-fold decrease in apparent plasma clearance (CL/f) being observed in the patients. Although the plasma unbound fraction of bendazac is increased in patients (the drug is highly bound to plasma albumin), the apparent volume of distribution (V/f) is unchanged. In consequence, the half-life of bendazac is increased two-fold in the patients. Impairment of metabolism decreases the formation of 5-hydroxybendazac, but metabolism remains the main route of its elimination. Renal excretion of bendazac accounts for about 10% of the dose in both patients with cirrhosis and healthy subjects. We conclude that in patients with severe hepatic insufficiency the daily dose of bendazac-lysine should be halved.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N2d8e798375684560bd735d266822432c
32 Nc85aa537d2ab4cb5b1a03e4289d64425
33 sg:journal.1054337
34 schema:name The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis
35 schema:pagination 391-396
36 schema:productId N1f3d992681f04a5f8f4679cafbf2c300
37 N4f35a5d4937a4c9bbbaf94f14fc69201
38 Na46fa74db6bb4e269a1cae8be2e35698
39 Nd8045796d7514088a2acadce17d96b53
40 Nd92d43d41d62439a9775b8f523536f14
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036705253
42 https://doi.org/10.1007/bf00561370
43 schema:sdDatePublished 2019-04-11T13:53
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher Nda423e709041470fb26f4aa6ae02e918
46 schema:url http://link.springer.com/10.1007/BF00561370
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N0f52908a78ac425da0ca95213d63862a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Protein Binding
52 rdf:type schema:DefinedTerm
53 N1f3d992681f04a5f8f4679cafbf2c300 schema:name dimensions_id
54 schema:value pub.1036705253
55 rdf:type schema:PropertyValue
56 N2d09cdf666e24fa2953c3e253534a356 schema:name Centre de Recherche Delalande, Rueil Malmaison, France
57 rdf:type schema:Organization
58 N2d8e798375684560bd735d266822432c schema:volumeNumber 35
59 rdf:type schema:PublicationVolume
60 N32991e3b88a74149bd3520b1fcfa4c8b rdf:first sg:person.01205714133.23
61 rdf:rest Nba23dbc1d34a4ff49301ffef504dc16e
62 N47ec7259d5e244ecb3c02f29212f2b5c rdf:first sg:person.0763747335.92
63 rdf:rest Nce84b93eb3a542afac8f81305c05cfd0
64 N4f35a5d4937a4c9bbbaf94f14fc69201 schema:name nlm_unique_id
65 schema:value 1256165
66 rdf:type schema:PropertyValue
67 N4f6fd1b97bca418aabf7d47a8913e1b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Liver Cirrhosis
69 rdf:type schema:DefinedTerm
70 N559425129ab44137a692a8a8847bfa60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Indazoles
72 rdf:type schema:DefinedTerm
73 N628b219d109843a1abcfc4617dc88a98 schema:name Centre de Recherche Delalande, Rueil Malmaison, France
74 rdf:type schema:Organization
75 N82189d8f685d4cf68e82cf10da8ba884 rdf:first sg:person.01326516170.03
76 rdf:rest Nf84198d9db2649698ef85c8ce1b0508f
77 N9cf03ad30c1f4df0a7e401342ba5ac98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Middle Aged
79 rdf:type schema:DefinedTerm
80 Na1ab75310fe740bf913533b4140fc35a schema:name Centre de Recherche Delalande, Rueil Malmaison, France
81 rdf:type schema:Organization
82 Na46fa74db6bb4e269a1cae8be2e35698 schema:name doi
83 schema:value 10.1007/bf00561370
84 rdf:type schema:PropertyValue
85 Na4c7e67fdfa64ee2b9bbe4b6bf743f74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Female
87 rdf:type schema:DefinedTerm
88 Naefd3b052e654fcd88caa2bcc93c71d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Pyrazoles
90 rdf:type schema:DefinedTerm
91 Nba23dbc1d34a4ff49301ffef504dc16e rdf:first sg:person.01135446267.07
92 rdf:rest N47ec7259d5e244ecb3c02f29212f2b5c
93 Nc6540cf887984a008f00d8dd18ffa74f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Blood Proteins
95 rdf:type schema:DefinedTerm
96 Nc85aa537d2ab4cb5b1a03e4289d64425 schema:issueNumber 4
97 rdf:type schema:PublicationIssue
98 Nce84b93eb3a542afac8f81305c05cfd0 rdf:first sg:person.01347523716.32
99 rdf:rest rdf:nil
100 Nd16168e8d3484f289c6818015e0f9532 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Male
102 rdf:type schema:DefinedTerm
103 Nd8045796d7514088a2acadce17d96b53 schema:name pubmed_id
104 schema:value 3197747
105 rdf:type schema:PropertyValue
106 Nd92d43d41d62439a9775b8f523536f14 schema:name readcube_id
107 schema:value aed9c08ebcccf18e097d74a420ab76fe12092edbcba83769b9a191e88f3b5af9
108 rdf:type schema:PropertyValue
109 Nda423e709041470fb26f4aa6ae02e918 schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 Ne4ff77b408364620a95de595410b91ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Humans
113 rdf:type schema:DefinedTerm
114 Ne7ef6fe7e4d0441a9fc057274a1f636b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Aged
116 rdf:type schema:DefinedTerm
117 Nf84198d9db2649698ef85c8ce1b0508f rdf:first sg:person.0720752245.38
118 rdf:rest N32991e3b88a74149bd3520b1fcfa4c8b
119 Nf96a6baba2564660a7551b596293adbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Adult
121 rdf:type schema:DefinedTerm
122 Nfd3ce03afb2c4778afacda7104b94e9c rdf:first sg:person.01177602577.96
123 rdf:rest N82189d8f685d4cf68e82cf10da8ba884
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
128 schema:name Clinical Sciences
129 rdf:type schema:DefinedTerm
130 sg:journal.1054337 schema:issn 0031-6970
131 1432-1041
132 schema:name European Journal of Clinical Pharmacology
133 rdf:type schema:Periodical
134 sg:person.01135446267.07 schema:affiliation N2d09cdf666e24fa2953c3e253534a356
135 schema:familyName Thiola
136 schema:givenName A.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135446267.07
138 rdf:type schema:Person
139 sg:person.01177602577.96 schema:affiliation N628b219d109843a1abcfc4617dc88a98
140 schema:familyName Rovei
141 schema:givenName V.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177602577.96
143 rdf:type schema:Person
144 sg:person.01205714133.23 schema:affiliation Na1ab75310fe740bf913533b4140fc35a
145 schema:familyName Ego
146 schema:givenName D.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205714133.23
148 rdf:type schema:Person
149 sg:person.01326516170.03 schema:affiliation https://www.grid.ac/institutes/grid.414295.f
150 schema:familyName Escourrou
151 schema:givenName J.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326516170.03
153 rdf:type schema:Person
154 sg:person.01347523716.32 schema:affiliation https://www.grid.ac/institutes/grid.414282.9
155 schema:familyName Houin
156 schema:givenName G.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347523716.32
158 rdf:type schema:Person
159 sg:person.0720752245.38 schema:affiliation https://www.grid.ac/institutes/grid.414282.9
160 schema:familyName Campistron
161 schema:givenName G.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720752245.38
163 rdf:type schema:Person
164 sg:person.0763747335.92 schema:affiliation https://www.grid.ac/institutes/grid.414295.f
165 schema:familyName Ribet
166 schema:givenName A.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763747335.92
168 rdf:type schema:Person
169 sg:pub.10.1007/bf00637567 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019827959
170 https://doi.org/10.1007/bf00637567
171 rdf:type schema:CreativeWork
172 sg:pub.10.2165/00003088-197702010-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048454128
173 https://doi.org/10.2165/00003088-197702010-00003
174 rdf:type schema:CreativeWork
175 https://app.dimensions.ai/details/publication/pub.1081861849 schema:CreativeWork
176 https://app.dimensions.ai/details/publication/pub.1082164662 schema:CreativeWork
177 https://doi.org/10.1002/jps.2600660402 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036399043
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1002/jps.2600680948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023750024
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/0006-2952(81)90151-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048734253
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/0010-4809(78)90017-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012957660
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/0163-7258(81)90077-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010634790
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/s0031-6989(83)80066-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007332006
188 rdf:type schema:CreativeWork
189 https://www.grid.ac/institutes/grid.414282.9 schema:alternateName Hôpital Purpan
190 schema:name Unité de Pharmacocinétique Clinique, C.H.U. Purpan, Toulouse, France
191 rdf:type schema:Organization
192 https://www.grid.ac/institutes/grid.414295.f schema:alternateName Hôpital Rangueil
193 schema:name Service des Maladies de l'Appareil Digestif, C.H.U. Rangueil, Toulouse, France
194 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...